The nerve function improved better in PE group than in the IVIG group. The treatment effectiveness in the PE and IVIG groups after 2 weeks were 96% and 79%, respectively. PE and IVIG significantly reduced blood immunoglobulins IgG, IgA, IgM, C3, and C4 in GBS patients, but they were significantly lower in the PE group than in the IVIG group. The gene discussed is CD79A; the disease is Guillain-Barre syndrome.